Haematite-TZ Tablet is a combination pharmaceutical formulation containing Ferrous Ascorbate (100 mg), Folic Acid (1.5 mg), and Zinc (22.5 mg), designed to address and prevent nutritional deficiencies commonly associated with anemia and impaired hematopoiesis. Ferrous Ascorbate serves as an effective source of elemental iron, facilitating hemoglobin synthesis and improving oxygen transport in the bloodstream. Folic Acid, a vital B-vitamin, plays a crucial role in DNA synthesis and red blood cell maturation, thereby aiding in the prevention of megaloblastic anemia. Zinc, an essential trace element included at 22.5 mg, supports immune function, enzymatic reactions, and cellular metabolism, contributing to overall hematologic health. Haematite-TZ is indicated for the treatment and prophylaxis of iron deficiency anemia, particularly in populations with increased iron requirements such as pregnant and lactating women, children, and individuals with chronic blood loss. The combination enhances absorption and bioavailability, reducing gastrointestinal side effects commonly associated with iron therapy. It is recommended to be administered under medical supervision, with dosage adjusted according to the severity of deficiency and patient response. Patients should be monitored for potential adverse effects, including gastrointestinal discomfort and hypersensitivity reactions. Haematite-TZ Tablet represents a comprehensive approach to correcting anemia and supporting hematologic and immune system function.